Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FJUU0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,977
Award facts
- Contract value 100% obligated
- $28,977.45 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $28,977.45 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml auto-injector units. The award, issued on November 28, 2025, with an ultimate completion date of December 1, 2025, utilizes firm fixed-price pricing with no set-aside designation, allowing the contractor to compete on an unrestricted basis. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors for pharmaceutical supply to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group's PPV-G GEN V prime contract, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 with a completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. The company's established performance across numerous delivery orders spanning diverse therapeutic categories—including oncology treatments, immunosuppressants, biologics, vaccines, and specialty pharmaceuticals—demonstrates its capability to support the recurring and specialized medical supply requirements of the military healthcare system globally. The absence of subcontractor relationships and consistent competitive awards without set-aside designations reflect DMS Pharmaceutical Group's competitive strength within the federal pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FJUU0?
SPE2DR26FJUU0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 28, 2025.
How much is contract SPE2DR26FJUU0 worth?
The government has obligated $28,977 on SPE2DR26FJUU0.
Is contract SPE2DR26FJUU0 an order under another contract?
Yes. SPE2DR26FJUU0 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUU0 competed?
The extent of competition for SPE2DR26FJUU0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award